Maria Wysocka

Maria Wysocka

Auto-generated profile, based on publicly available information

Maria Wysocka

Department of Dermatology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2024 in Science Immunology
Verified
Journal Article
Closed access
RPRuchi P. Patel
Ruchi P. Patel
GGGuido Ghilardi
Guido Ghilardi
YZYunlin Zhang
Yunlin Zhang
YCYi-Hao Chiang
Yi-Hao Chiang
WXWei Xie
Wei Xie
MRMarco Ruella
Marco Ruella
Most patients treated with US Food and Drug Administration (FDA)–approved chimeric antigen receptor (CAR) T cells eventually experience disease progression. Furthermore, CAR T cells have not been curative against solid cancers and several hematological malignancies such as T cell lymphomas, which have very poor prognoses. One of the main barriers to the clinical success of adoptive T cell immunotherapies is CAR T cell dysfunction and lack of expansion and/or persistence after infusion. In this study, we found that CD5 inhibits CAR T cell activation and that knockout (KO) of CD5 using CRISPR-Cas9 enhances the antitumor effect of CAR T cells in multiple hematological and solid cancer models. Mechanistically, CD5 KO drives increased T cell effector function with enhanced cytotoxicity, in vivo expansion, and persistence, without apparent toxicity in preclinical models. These findings indicate that CD5 is a critical inhibitor of T cell function and a potential clinical target for enhancing T cell therapies.

4 January 2022 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
SMSpandana Maddukuri
Spandana Maddukuri
JPJay Patel
Jay Patel
DDDe Anna Diaz
De Anna Diaz
KCKristen L. Chen
Kristen L. Chen
MWMaria Wysocka
Maria Wysocka
VWVictoria P WERTH
Victoria P WERTH
Background: Lenabasum is a cannabinoid type 2 receptor (CB2R) reverse agonist that demonstrates anti-inflammatory effects in vivo and in vitro in dermatomyositis (DM) and is currently being investigated for therapeutic potential. The purpose of our study is to investigate CB2R distribution as well as the effects of lenabasum in DM. Methods: Immunohistochemistry staining (IHC) was utilized to examine immune cell and cytokine production changes in lesional DM skin biopsies from lenabasum and placebo-treated patients. CB2R expression in various immune cell populations within DM skin was investigated with image mass cytometry (IMC), whereas flow cytometry elucidated CB2R expression in DM peripheral blood mononuclear cells (PBMCs) as well as cytokine production by CB2R-expressing cell populations. Results: After 12 weeks of lenabasum treatment, IHC staining showed that CD4+ T cells, CB2R, IL-31, IFN-γ, and IFN-β cytokines were downregulated. IFN-γ and IFN-β mRNA decreased in lesional DM skin but not in PBMCs. IMC findings revealed that CB2R was upregulated in DM lesional skin compared to HC skin and DM PBMCs (p<0.05). In DM skin, CB2R was upregulated on dendritic cells, B cells, T cells, and macrophages while dendritic cells had the greatest expression in both DM skin and PBMCs (p<0.05). These CB2R+ cells in the skin produce IL-31, IL-4, IFN-γ, and IFN-β. Conclusion: Our findings of differential CB2R expression based on location and cell type suggest modes by which lenabasum may exert anti-inflammatory effects in DM and highlights dendritic cells as potential therapeutic targets.

9 June 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
MWMaria Wysocka
Maria Wysocka
NJNeha Jariwala
Neha Jariwala
KZKevin Zhang
Kevin Zhang
BBBernice Benoit
Bernice Benoit
ARAlain H. Rook
Alain H. Rook
Sézary syndrome (SS), a leukemic form of cutaneous T cell lymphoma (CTCL), is a rare T-cell malignancy which is defined by circulating malignant CD4+CD26− T cells [1]. It is characterized by severe...